







U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<div> <div>Complete if Known</div> <div> <div>Application Number</div> <div>10/587,767</div> </div> <div> <div>Filing Date</div> <div>10-17-06</div> </div> <div> <div>First Named Inventor</div> <div>Lene Møller</div> </div> <div> <div>Art Unit</div> <div>1656</div> </div> <div> <div>Examiner Name</div> <div>Marsha M. Tsay</div> </div> <div> <div>Attorney Docket Number</div> <div>13323-105002</div> </div> </div>	
<div> <div>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</div> <div>(Use as many sheets as necessary)</div> </div>					
Sheet	4	of	13		

[illegible]

FOREIGN PATENT DOCUMENTS								
Examiner Initial *	Cite No.	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>o</sup>
		Country <sup>3</sup> Code	Number <sup>4</sup>	Kind Code (if known) <sup>5</sup>				
		<del>GB</del>	<del>GB 697603</del>		<del>09-13-49</del>			
		<del>JP</del>	<del>JP 01 130510</del>		<del>05-23-80</del>			
		<del>JP</del>	<del>JP 00254146</del>					
		JP	JP 60214728		10-28-85	Sakamoto et al.		
		<del>JP</del>	<del>JP 62 221357</del>		<del>09-29-87</del>			
		<del>JP</del>	<del>JP 62070318</del>					
		PC	WO 0009018		02-24-00	Yang et al.		
		PC	WO 0018301		04-06-00	Epstein et al.		
		PC	WO 0027327		05-18-00	Cochrum et al.		
		PC	WO 0074742		12-14-00	Zahradka et al.		

Examiner Signature	/Marsha Tsay/	Date Considered	12.11.09
--------------------	---------------	-----------------	----------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional) 2. See Kinds codes of USPTO patent Documents. at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.  
3. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3.) 4. For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786.9199) and select option 2.*

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MT/





Under the Paperwork reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<div>Complete if Known</div> <table border="1"> <tr> <td>Application Number</td> <td>10/587,767</td> </tr> <tr> <td>Filing Date</td> <td>10-17-06</td> </tr> <tr> <td>First Named Inventor</td> <td>Lene Møller</td> </tr> <tr> <td>Art Unit</td> <td>1656</td> </tr> <tr> <td>Examiner Name</td> <td>Marsha M. Tsay</td> </tr> <tr> <td>Attorney Docket Number</td> <td>13323-105002</td> </tr> </table>		Application Number	10/587,767	Filing Date	10-17-06	First Named Inventor	Lene Møller	Art Unit	1656	Examiner Name	Marsha M. Tsay	Attorney Docket Number	13323-105002
Application Number	10/587,767																
Filing Date	10-17-06																
First Named Inventor	Lene Møller																
Art Unit	1656																
Examiner Name	Marsha M. Tsay																
Attorney Docket Number	13323-105002																
<div>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</div> <div>(Use as many sheets as necessary)</div>																	
Sheet	7	of	13														

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initial *	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, columns, Lines, Where Relevant Passages or Relevant Figures Appear	Page
		Country <sup>3</sup> Code	Number <sup>4</sup>	Kind Code (if known) <sup>5</sup>				
		PC	WO 05044285		05-19-05	<del>Wittig</del> Kim et al.		
		PC	WO 05062889		07-14-05	<del>Biological Corp.</del> Campbell et al.		
		PC	WO 06034568		04-06-06	<del>Cohesion Corporation</del> Ditzio et al.		
		PC	WO 06063758		06-22-06	<del>Immune</del> Pastorello et al.		
		PC	WO 2004028583		04-08-04	<del>Cohesion Corporation.</del> Gravett et al.		
		PC	WO 2004035629		04-29-04	<del>Adams et al.</del> De Luca et al.		
		PC	WO 2005044285		05-19-05	<del>Brigham &amp; Women's Hospital</del> Kim et al.		
		PC	WO 9013320		11-15-90	<del>Imax</del> Munck et al		
		PC	WO 9306802		04-15-93	<del>Fidia</del> Rolf		
		PC	WO 9306855		04-15-93	<del>Chong</del> Hedner et al.		
Examiner Signature	/Marsha Tsay/					Date Considered	12.11.09	

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 509. Draw line through citation if not in conformance and not considered. Include of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional) 2. See Kinds codes of USPTO patent Documents, at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.  
3. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3.) 4. For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.1  
6. If possible, 6. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786.9199) and select option 2.

/M.T./  
02.23.11

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MT/









Under the Paperwork reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/587,767
				Filing Date	10-17-06
				First Named Inventor	Lene Møller
				Group Art Unit	1656
				Examiner Name	Marsha M. Tsay
Sheet	11	of	13	Attorney Docket Number	13323-105002

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initial *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		SOULES ET AL, Am. J. Obstet. Gynecol., Vol. 143, pg. 829-834, 1982, "The prevention of postoperative pelvic adhesions: An animal study comparing barrier methods with Dextran 70"	
		MAXSON ET AL, Gynecol. Obstet. Invest., Vol. 26, pg. 160-165, 1988, "Efficacy of a modified oxidized cellulose fabric in the prevention of adhesion formation"	
		Quintavalla et al., Biomaterials 2002 Jan;23(1):109-119. Fluorescently labeled mesenchymal stem cells (MSC) maintain multilineage potential and can be detected following articular cartilage defects	
		ELLEGALA ET AL, Neurosurgery, August 2002, Vol. 51, pg. 513-516, "Use of FloSeal Hemostatic Sealant In Transsphenoidal Pituitary surgery: technical note"	
		CHOI YS ET AL, J Biomed Mater Res 1999; 48 (5), pg. 631-639, "Studies on gelatin-containing artificial skin: II. Preparation and characterization of cross-linked gelatin-hyaluronate sponge"	
		LAURENT ET AL, AM. J. Otolaryngol, Vol. 7, pg. 181-186, 1986, "Hyaluronic acid reduces connective tissue formation in middle ears filled with absorbable gelatin sponge: an experimental study"	
		KOCAK, ET AL., Fertility and Sterility, Vol. 72, No. 5, pg. 873-878, November 1999, "Reduction of adhesion formation with cross-linked hyaluronic acid after peritoneal surgery in rats"	
		HILL-WEST, ET AL., Fertility and Sterility, Vol. 62, No. 3, pg. 630-634, "Efficacy of a resorbable hydrogel barrier, oxidized regenerated cellulose and hyaluronic acid in the prevention of ovarian adhesions in a rabbit model" <b>1994</b>	
		CHANGEZ ET AL, Biomaterials, 2005, Vol. 26, No. 14, pg. 2095-2104, "Efficacy of antibiotics-loaded interpenetrating network (IPNs) hydrogel based on poly (acrylic acid) and gelatin for treatment of experimental osteomyelitis: in vivo study"	
		RAFTERY, BR. J. Surg., Vol. 67, pg. 57-58, 1980, "Absorbable Haemostatic materials and intraperitoneal adhesion formation"	
		SHUSHAN, ET AL., Journal of Reproductive Medicine, Vol. 39, pg. 398-402, 1994, "Hyaluronic acid for preventing experimental postoperative intraperitoneal adhesions"	

Examiner Signature	/Marsha Tsay/	Date Considered	12.11.09
--------------------	---------------	-----------------	----------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Applicants unique citation designation number. (optional) 2. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MT/

Under the Paperwork reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			Application Number	10/587,767	
			Filing Date	10-17-06	
			First Named Inventor	Lene Møller	
			Group Art Unit	1656	
			Examiner Name	Marsha M. Tsay	
Sheet	12	of	13	Attorney Docket Number	13323-105002

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initial *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		LARSSON, ET AL., Acta Chir. Scand., Vol. 26, pg. 375-378, 1978, "Surgicel- An absorbable hemostatic material- In prevention of peritoneal adhesions in rats"	
		DEMBO, M. A ET AL, Lech. Prep. Krovi. Tkanei, pg. 139-40, 1974, "Antiseptic hemostatic preparations, their properties and study"	
		VAN DER SALM T.J. ET AL, J. of Thoracic and Cardiovascular Surgery, 1989, Vol. 98, No. 4, pg. 618-622, "Reduction of sternal infection by application of topical vancomycin"	
		REIJNEN, ET AL., Arch Surg., Vol. 134, pg. 997-1001, September 1999, "Prevention of Intra-Abdominal Abscesses and adhesions using a hyaluronic acid solution in a rat peritonitis model"	
		WACHOL-DREWEK ET AL, Biomaterials 17, pg. 1733-1738, 1996, "Comparative Investigation of drug delivery of collagen implants saturated in antibiotic solutions and a sponge containing gentamicin"	
		"FloSeal Matrix Hemosealant. Instructions for use". Accessed online August 17, 2005 at <a href="http://www.ctsnet.org/file/vendors/931/pdf/140.pdf">http://www.ctsnet.org/file/vendors/931/pdf/140.pdf</a>	
		DROGNITZ ET AL, Indection Germany (Munich), 2006, 34 (1), pg. 29-34, "Release of vancomycin and teicoplanin from a plasticized and resorbable gelatin sponge: in vitro investigation of a new antibiotic delivery system with glycopeptides"	
		DE IACO, ET AL., Surgery, Vol. 130, pg. 60-64, 2001, "Efficacy of a Hyaluronan Derivative gel in postsurgical adhesion prevention in the presence of inadequate hemostasis"	
		Sakurabayashi et al., Gastroenterological Endoscopy 30(10) Oct 1988. Clinical evaluation of new hemostatic agent for hemostasis from biopsy wounds in the liver	
		LUENGO, ET AL., , Fertility and Sterility, Vol. 29, No. 4, April 1978, "Prevention of peritoneal adhesions by the combined use of Spongostan and 32% Dextran 70: an experimental study in pigs"	
		Spence et al., Cancer 1975 Feb;35(2).326-341. Cerebellar capillary hemangioblastoma: its histogenesis studied by organ culture and electron microscopy.	

Examiner Signature	/Marsha Tsay/	Date Considered	12.11.09
--------------------	---------------	-----------------	----------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Applicants unique citation designation number. (optional) 2. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.  
SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MT/

Under the Paperwork reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/587,767
				Filing Date	10-17-06
				First Named Inventor	Lene Møller
				Group Art Unit	1656
				Examiner Name	Marsha M. Tsay
Sheet	13	of	13	Attorney Docket Number	13323-105002

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initial *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		HONG ET AL, Biomaterials, 2001, 22 (20), pg. 2777-2783, "Study on gelatin-containing artificial skin IV: a comparative study on the effect of antibiotic and EGF on cell proliferation during epidermal healing"	
		OZ ET AL, Ann Thorac Surg 2000, Vol. 69, pg. 1376-1382, 2000, "Controlled clinical trial of a novel hemostatic agent in cardiac surgery"	
		WEST, ET AL., The Journal of reproductive medicine, Vol. 41, pg. 149-154, 1996, "Efficacy of adhesion barriers, resorbable hydrogel, oxidized regenerated cellulose and hyaluronic acid"	
		SANFILIPPO ET AL, Fertility and sterility, Vol. 33, No. 3, pg. 311-316, March 1980, "Comparison of avitene, topical thrombin and Gelfoam, as sole hemostatic agent in tuboplasties"	
		WIESENTHAL ET AL, The Journal of Otolaryngology, 1999, Vol. 28, No. 5, pg. 260-265, "New method for packing the external auditory canal, middle ear space, and mastoid cavities after otologic surgery"	
		HAE-WON ET AL, J. of Biomedical Materials Research, 2005, 74B (2), pg. 686-698, "Porous scaffolds of gelatin-hydroxyapatite nanocomposites obtained by biometric approach: Characterization and antibiotic drug release"	
		LI, ET AL., Arch Otolaryngol Head Neck Surg., Vol. 127, pg. 534-539, May 2001, "Evaluation of Esterified Hyaluronic Acid as middle ear-packing material"	
		YUESONG ET AL, Intern. des Services de San. des Forces Armees, September 1999, Vol. 72, No. 7-9, pg. 194-196, "Design and experimental study of a slow-release antibiotic membrane implant in surgery wound"	
		HILL ET AL, J. Thorac Cardiovasc Surg 1994, Vol. 108, pg. 1151-1152, "Use of microfibrillar collagen hemostat (Avitenet) and thrombin to achieve hemostats after median sternotomy"	

Examiner Signature	/Marsha Tsay/	Date Considered	12.11.09
-----------------------	---------------	--------------------	----------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Applicants unique citation designation number. (optional) 2. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MT/